barriers of IP that make medicines high priced and inaccessible, FTA negotiations often come with stronger requirements such as (TRIPs-plus) and in country actors like lobbyist to comply with demands with US and EU, and cases for infringement and constant pressure to amend IP to align with TRIP plus – need measures to safeguard our drug security and allow GPO to have safety measures to guarantee access to drugs and people’s draft bill to medicine legislation has also been delayed because int. law companies distort that drugs are high in price because R&D